advertisement

WGA Rescources

Abstract #119538 Published in IGR 25-1

Research progress of retinal neuroprotective drugs for glaucoma

Liu XY; Sun XH
Chinese Journal of Ophthalmology 2024; 60: 860-869


Glaucoma is a neural degenerative disease characterized by progressive loss of retinal ganglion cells, resulting in irreversible visual field loss, low vision, and total blindness. Despite the fact that the pathological elevation of intraocular pressure is a major risk factor for glaucoma, it is imperative to develop therapies that can prevent and block retinal ganglion cell injury and apoptosis in addition to reducing intraocular pressure. Drug therapy is the primary treatment for glaucoma in most clinical cases. This article provides reference information for the clinical treatment of glaucoma by summarizing and analyzing the medications that have direct optic nerve protection in clinical or preclinical trials, based on the most recent research results from both domestic and international studies.

Department of Ophthalmology, Eye & ENT Hospital of Fudan University, NHC Key Laboratory of Myopia and Related Eye Diseases, Key Laboratory of Myopia and Related Eye Diseases, Chinese Academy of Medical Science, Shanghai 200031, China.

Full article

Classification:

15 Miscellaneous



Issue 25-1

Change Issue


advertisement

Nidek